{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"2.8","value":"1.9"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"9.2","value":"6.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) FACT-Ovarian Symptom Index (FOSI-18) is a questionnaire, for completion by patients, designed to assess the impact of cancer therapy on ovarian cancer-related symptoms and is based on numerical point scoring of symptoms. The DRS-P subscale of the questionnaire is specifically designed to assess physical symptoms of ovarian cancer and evaluate changes in the subscale point score in individual assessments over time. This study looked at the time to a 4-point reduction in subscale score as an indicator of improvement in disease-related physical symptoms on cancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG000","title":"Rucaparib 600 mg Tablets"},{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG001","title":"Placebo Tablets"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat: All patients randomized","reportingStatus":"POSTED","timeFrame":"Screening, Day 1 of each treatment cycle, Treatment Discontinuation visit, and 28-day Follow-up visit. Total follow-up was up to approximately 6.4 years.","title":"Time to a 4-point Decrease in the Disease-related Symptoms - Physical (DRS-P) Subscale of the FOSI-18","type":"SECONDARY","unitOfMeasure":"Months"}